BUSULFAN AND CYCLOPHOSPHAMIDE FOR CYTOREDUCTION OF PATIENTS WITH ACUTE AND CHRONIC LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES UNDERGOING ALLOGENEIC BONE MARROW TRANSPLANTATION WHO CANNOT BE TREATED WITH TOTAL BODY IRRADIATION
OBJECTIVES: I. Determine the effect of marrow ablation with high dose
busulfan/cyclophosphamide on engraftment, incidence of posttransplant relapse, incidence and
severity of graft versus host disease (GVHD), and incidence and severity of nonGVHD
posttransplant complications in patients with acute or chronic leukemia or myelodysplastic
syndrome who are eligible for allogeneic bone marrow transplants from HLA
identical/compatible donors but who cannot or should not receive total body irradiation as
part of their cytoreductive regimen.
OUTLINE: 2-Drug Combination Cytoreductive Chemotherapy followed by Bone Marrow Transplant
with, as indicated, CNS Prophylaxis. Busulfan, BU, NSC-750; Cyclophosphamide, CTX,
NSC-26271; followed by Allogeneic Bone Marrow, AlBM; with, as indicated, Intrathecal
Cytarabine, IT ARA-C, NSC-63878.
PROJECTED ACCRUAL: At least 15 patients will be accrued for this study.
Primary Purpose: Treatment
Esperanza B. Papadopoulos, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|